E-MAIL

pinghsuan.h@mail.ndmctsgh.edu.tw

Experience

2022/2–present Faculty, National Defense Medical Center
2011/1–2017/8 Pharmacist, Tri-Service General Hospital
2015/10–2016/3 Visiting researcher, Health Economics and Health Technology, School of Health and Wellbeing, University of Glasgow
2008/09–2010/12 Pharmacist, Tri-Service General Hospital Penghu Branch
2005/08–2008/08 Military service in the R.O.C. Army

Research Interest

Health Technology Assessment, Cost of Illness, and Evidence Synthesis

Short Biography

Shawn’s research interests are in evidence synthesis and the use of real-world evidence in health economics. His PhD estimated the cost of illness in people with rheumatoid arthritis/musculoskeletal disorders in Scotland and Tanzania. He is currently developing his new team and has been involved in several grants, including economic evaluations of new health technologies in CVDs and oncology and the cost-of-illness for patients living on offshore islands. In addition, he teaches Pharmacoeconomics and supervises undergraduate and MSc students at the National Defense Medical Center.

Publications

(Bold & Star-sign*: correspondent)
Papers
1. Hsieh P-H*, Geue C , Wu O, McIntosh E, Siebert S. (2022) How do multiple long-term conditions impact on the cost-of-illness in early rheumatoid arthritis?. RMD Open 2022;8:e002454. doi:10.1136/rmdopen-2022-002454 (IF: 5.806, 7/34, 2021 JCR)
2. Quinn T, Burton J, Carter B, Cooper C, Dwan K, Field R, Freeman S, Geue C, Hsieh P-H, McGill K, Nevill C, Rana D, Sutton A, Taylor-Rowan M, Xin X. Following the Science? Comparison of methodological and reporting quality of COVID-19 and other research from the first wave of the pandemic. BMC Medicine 2020 19(1), 1-10. (IF: 11.150, 21/172, 2021 JCR)
3. Hsieh P-H*, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Annals of the Rheumatic Diseases 2020;79:771 (IF: 27.973, 3/34, 2021 JCR)
Presentations
1. Poster: Estimating the quality of life and economic impact of arthritis in Tanzania. British Society for Rheumatology, Glasgow, UK, April 2022.
2. Oral presentation: How Does Multimorbidity Impact on the Cost-of-Illness in Patients with Rheumatoid Arthritis? Results from the SERA study. Health Technology Assessment International Annual Meeting, Manchester, UK, June 2021. (shortlisted for the best student oral presentation award)
3. Poster: How does multimorbidity impact on the direct and indirect costs in patients with rheumatoid arthritis? European Alliance of Associations for Rheumatology Congress, Paris, France, June 2021.
4. Poster: Impact on Costs in Patients with early Rheumatoid Arthritis. International Society for Pharmacoeconomics and Outcomes Research Asia Pacific Virtual Conference. September 2020.
5. Oral presentation: Impact of Biologics on Rheumatoid Arthritis: How Have Costs Evolved? Health Technology Assessment International Annual Meeting, Cologne, Germany, June 2019.
6. Poster: The Evolving Cost of Illness of Rheumatoid Arthritis: A Systematic Review. Poster presentation. International Society for Pharmacoeconomics and Outcomes Research Asia Pacific Congress, Tokyo, Japan, September 2018.
7. Poster: The Evolving Drug Expenses and Healthcare Costs of Rheumatoid Arthritis: A Systematic Review. Poster presentation. International Pharmaceutical Federation (FIP) World Congress, Glasgow, UK, September 2018.